directly attributable to its administration. Further clinical evaluation is on-going.
|
|
Megakaryocyte Growth and Development Factor (MGDF) in laboratory
tests has been shown to stimulate bone marrow to make platelets by inducing
the marrow progenitor cells to become megakaryocytes, the cells wich make
platelets. Administration of MGDF to humans was associated with a dose-related
increase in the platelet count with maximum levels observed between days
12-18. Platelets had normal appearance and functioned normally in assays
of platelet aggregation and ATP-release. There was no evidence of platelet
activation as assessed by platelet surface markers. The earliest detectable
effect of MGDF was an increase in early (reticulated) platelets by day
3-4. MGDF also hastened recovery from thrombocytopenia when given after
myelosuppressive chemotherapy. MGDF caused mobilisation into the blood
of progenitor cells of multiple haemopoietic lineages, and was synergistic
with G-CSF in this action after chemotherapy. MGDF was well tolerated with
no adverse effects
directly attributable to its administration. Further clinical evaluation is on-going. |